↓ Skip to main content

Dove Medical Press

Article Metrics

Treatment of hemophilia B: focus on recombinant factor IX

Overview of attention for article published in Biologics: Targets & Therapy, February 2013
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • Among the highest-scoring outputs from this source (#23 of 219)
  • High Attention Score compared to outputs of the same age (85th percentile)
  • High Attention Score compared to outputs of the same age and source (80th percentile)

Mentioned by

4 patents
1 Wikipedia page


24 Dimensions

Readers on

66 Mendeley
1 CiteULike
Treatment of hemophilia B: focus on recombinant factor IX
Published in
Biologics: Targets & Therapy, February 2013
DOI 10.2147/btt.s31582
Pubmed ID

Massimo Franchini, Frattini, Crestani, Sissa, Bonfanti


Hemophilia B is a recessive X-linked bleeding disorder characterized by deficiency of the coagulation factor IX (FIX). In hemophilia B patients the severity of the bleeding phenotype is related to the degree of the FIX defect. Hemophilia B treatment has improved greatly in the last 20 years with the introduction first of plasma-derived and then of recombinant FIX concentrates. Replacement therapy may be administered through on-demand or prophylaxis regimens, but the latter treatment modality has been shown to be superior in prevention of hemophilic arthropathy and in improvement of patients' quality of life. The purpose of this narrative review is to summarize the current knowledge on treatment strategies for hemophilia B, focusing on recombinant FIX products either clinically used or in development. There is only one rFIX product that is licensed to treat hemophilia B patients; from the analysis of the literature data presented in this review, the authors conclude that this rFIX product has demonstrated an excellent safety profile and excellent clinical efficacy for halting and preventing bleeds in hemophilia B patients. While prophylaxis has emerged as the best therapeutic strategy for such patients because of its ability to prevent hemophilic arthropathy and to improve patients' quality of life, the pharmacokinetically tailored dosing of rFIX is another key point when planning hemophilia B treatment, as it allows optimization of the factor concentrate usage. Further clinical studies are needed to better assess the safety and efficacy (ie, the incidence of adverse reactions and inhibitor development) of newer rFIX products.

Mendeley readers

The data shown below were compiled from readership statistics for 66 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
United Kingdom 1 2%
Canada 1 2%
Brazil 1 2%
Unknown 63 95%

Demographic breakdown

Readers by professional status Count As %
Student > Bachelor 11 17%
Researcher 11 17%
Student > Master 10 15%
Other 7 11%
Student > Ph. D. Student 6 9%
Other 12 18%
Unknown 9 14%
Readers by discipline Count As %
Biochemistry, Genetics and Molecular Biology 17 26%
Agricultural and Biological Sciences 14 21%
Medicine and Dentistry 12 18%
Engineering 3 5%
Pharmacology, Toxicology and Pharmaceutical Science 3 5%
Other 8 12%
Unknown 9 14%

Attention Score in Context

This research output has an Altmetric Attention Score of 9. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 05 November 2019.
All research outputs
of 16,569,218 outputs
Outputs from Biologics: Targets & Therapy
of 219 outputs
Outputs of similar age
of 153,955 outputs
Outputs of similar age from Biologics: Targets & Therapy
of 5 outputs
Altmetric has tracked 16,569,218 research outputs across all sources so far. Compared to these this one has done well and is in the 85th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 219 research outputs from this source. They receive a mean Attention Score of 5.0. This one has done well, scoring higher than 89% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 153,955 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 85% of its contemporaries.
We're also able to compare this research output to 5 others from the same source and published within six weeks on either side of this one. This one has scored higher than all of them